Safety, efficacy, and dosing comparison of once-daily OROS hydromorphone and immediate-release hydromorphone in patients with chronic non-cancer pain

被引：0
|
作者：
Bornhovd, K.
Richarz, U.
Berliner, M. N.
Thipphawong, J.
机构：
[1] Janssen Cilag Germany, Med & Sci Affairs, Neuss, Germany
[2] Janssen Cilag Europe, Med Affairs, Baar, Switzerland
[3] Univ Klinikum Gieben, Med Klin & Poliklin 3, Rodthohl, Germany
[4] ALZA Corp, Med Res, Mountain View, CA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2006年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：562 / 562
页数：1
相关论文
共 50 条
  • [31] COMPARATIVE EFFICACY OF A ONCE-DAILY CONTROLLED-RELEASE FORMULATION OF GLIPIZIDE AND IMMEDIATE-RELEASE GLIPIZIDE IN PATIENTS WITH NIDDM
    BERELOWITZ, M
    FISCHETTE, C
    CEFALU, W
    SCHADE, DS
    SUTFIN, T
    KOURIDES, IA
    DIABETES CARE, 1994, 17 (12) : 1460 - 1464
  • [32] Advances in the long-term management of chronic pain:: Recent evidence with OROS® hydromorphone, a novel, once-daily, long-acting opioid analgesic -: Introduction
    Cousins, Michael J.
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2007, 33 (02) : S1 - S3
  • [33] Complementary pharmacokinetic measures to further define the profile of once-daily OROS hydromorphone ER during single-dose and steady-state dosing
    Devarakonda, Krishna
    Vandenbossche, Joris
    Richarz, Ute
    SPRINGERPLUS, 2013, 2 : 1 - 9
  • [34] Safety and Efficacy of Once-Daily Hydromorphone Extended-Release Versus Twice-Daily Oxycodone Hydrochloride Controlled-Release in Chinese Patients With Cancer Pain: A Phase 3, Randomized, Double-Blind, Multicenter Study
    Yu, Shiying
    Shen, Wei
    Yu, Lu
    Hou, Yanyan
    Han, John
    Richards, Henry M.
    JOURNAL OF PAIN, 2014, 15 (08): : 835 - 844
  • [35] Results of a Double-blind, Placebo-controlled, Fixed-dose Assessment of Once-daily OROS® Hydromorphone ER in Patients with Moderate to Severe Pain Associated with Chronic Osteoarthritis
    Rauck, Richard
    Rapoport, Ronald
    Thipphawong, John
    PAIN PRACTICE, 2013, 13 (01) : 18 - 29
  • [36] Clinical efficacy of OROS® hydromorphone in patients suffering from severe chronic pain: A Study undertaken in routine clinical practice
    Stepanovic, Aleksander
    Pirc, Jelka
    Cavlovic, Slavica Lahajnar
    WIENER KLINISCHE WOCHENSCHRIFT, 2011, 123 (17-18) : 531 - 535
  • [37] Pharmacokinetics comparison between two formulations of lamotrigine: Once-daily extended-release vs twice daily immediate-release tablets
    Ali, Imran
    Oliver-Willwong, R.
    Tompson, D.
    Hammer, A.
    Vuong, A.
    Messenheimer, J.
    EPILEPSIA, 2007, 48 : 369 - 370
  • [38] Efficacy of a new once daily hydromorphone formulation in comparison with twice daily administration in chronic pain: a randomized, double-blind, cross-over study
    Nold, Gudrun Edelgard
    Maritz, Martina Alice
    Schwittay, Andreas
    Schumann, Claudia
    Rey, Helene
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (05) : 869 - 877
  • [39] COMPARISON OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CONTROLLED-RELEASE AND IMMEDIATE-RELEASE METOCLOPRAMIDE FOR THE MANAGEMENT OF CHRONIC NAUSEA IN PATIENTS WITH ADVANCED CANCER
    BRUERA, ED
    MACEACHERN, TJ
    SPACHYNSKI, KA
    LEGATT, DF
    MACDONALD, RN
    BABUL, N
    HARSANYI, Z
    DARKE, AC
    CANCER, 1994, 74 (12) : 3204 - 3211
  • [40] Exploring the Impact of Once-Daily OROS® Methylphenidate (MPH) on Symptoms and Quality of Life in Children and Adolescents with ADHD Transitioning From Immediate-Release MPH
    Kordon, Andreas
    Stollhoff, Kirsten
    Niederkirchner, Kaete
    Mattejat, Fritz
    Rettig, Klaus
    Schaeuble, Barbara
    POSTGRADUATE MEDICINE, 2011, 123 (05) : 27 - 38
12345